Back

State of the Art - SGLT2 inhibitors in cardiovascular disease

31 August 2019 (11:00 - 11:18)
Organised by:
Congress Presentation Part of: New frontiers: SGLT2 inhibitors in cardiorenal disease Risk Factors and Prevention ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Marc Sabatine

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail
Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58
Doctor T. Zelniker (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial
Doctor J. Udell (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes
Doctor C. Noergaard (Aalborg, DK)
Abstract Slides Video
Presentation thumbnail
Integrating SGLT2 inhibitors in diabetes treatment: a guide for cardiologists
Professor N. Sattar (Glasgow, GB)
Slides Video

Access the full session

Session thumbnail
New frontiers: SGLT2 inhibitors in cardiorenal disease

The Event

Event poster

ESC Congress 2019

31 August 2019 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Impact of SGLT2 inhibitor on mortality and cardiovascular outcomes in patients with type 2 diabetes mellitus with left main or multivessel coronary artery disease
27 August 2022
thumbnail
Webinar
SGLT2 inhibitors across the left ventricular function spectrum
24 September 2024
thumbnail
Congress Presentation
SGLT2 inhibitors for obesity
31 August 2024
thumbnail
Congress Session
Young Investigator Award (YIA) Basic Science
17 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources